ATYR1923 ( DrugBank: ATYR1923 )

---

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
84	サルコイドーシス	2

84. サルコイドーシス

---

臨床試験数 : 149 /  薬物数 : 227 - (DrugBank : 81) / 標的遺伝子数 : 82 - 標的パスウェイ数 : 167

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2018-004244-33-DE (EUCTR)	21/10/2019	15/07/2019	A safety study with multiple doses of intravenous (in the vein) ATYR1923 in patients with pulmonary sarcoidosis	A Randomized, Double-Blind, Placebo-Controlled Multiple Ascending Dose Study of Intravenous ATYR1923 in Patients with Pulmonary Sarcoidosis	Pulmonary Sarcoidosis MedDRA version: 20.0;Level: PT;Classification code 10037430;Term: Pulmonary sarcoidosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders ;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]	Product Name: ATYR1923 Product Code: ATYR1923 INN or Proposed INN: Not yet available Other descriptive name: iMod.Fc, H-Fcv3-N4	aTyr Pharma, Inc.	NULL	Not Recruiting			Female: yes Male: yes	36	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): no	Germany;United States
2	NCT03824392 (ClinicalTrials.gov)	January 29, 2019	28/1/2019	Study of Intravenous ATYR1923 for Pulmonary Sarcoidosis	A Randomized, Double-Blind, Placebo-Controlled Multiple Ascending Dose Study of Intravenous ATYR1923 in Patients With Pulmonary Sarcoidosis	Pulmonary Sarcoidosis	Biological: ATYR1923 1.0 mg/kg or placebo;Biological: ATYR1923 3.0 mg/kg or placebo;Biological: ATYR1923 5.0 mg/kg or placebo	aTyr Pharma, Inc.	Foundation for Sarcoidosis Research	Completed	18 Years	75 Years	All	37	Phase 1/Phase 2	United States